Titel
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006)
in Patients With Relapsing-Remitting Multiple Sclerosis
The Antelope Phase 3 Randomized Clinical Trial
Referenz
Bernhard Hemmer et al.,
JAMA Neurol. 2023; 80(3):298-307
Fachrichtungen
Indikationen
Multiple Sklerose
Wirkstoffe
Natalizumab